Symposium
Session Room: M1
Session Room: M1
Monday, June 29, 10:50 AM – 12:05 PM
Symposium 23:
Understanding and treating Attention Deficit Hyperactivity Disorder (ADHD)
Understanding and treating Attention Deficit Hyperactivity Disorder (ADHD)
This symposium brings together leading experts in computational psychiatry, neuroimaging, and genetics to parsing the heterogeneity of ADHD in relation to its mechanisms, comorbidities, neurotherapies. The session will highlight recent findings in neurocognitive pathways, genetics underlying comorbidities, novel neuromodulations for ADHD to shed new insights in mechanism and treatment of this disorder.
Prof Qiang Luo, PhD., Director, Centre for Computational Psychiatry, Institute of Brain Inspired Intelligence at Fudan University (P.R. China), will discuss his recent work on “ADHD: neurocognitive pathways”. ADHD is characterized by its clinical heterogeneity in symptoms and their trajectories1. However, both cognitive impairment and motivational dysfunction in the well-known ‘dual-pathway model for ADHD’ can be absent in about 30% of ADHD cases and cannot predict the persistence or remitting of the symptoms. He will present and discuss the emerging evidence that highlights the emotion dysregulation, proposing a new three-pathway model2, and the prediction of symptom course by longitudinal neuroimaging changes3.
Dr. Nagahide Takahashi, MD., PhD., Director, Department of Neurodevelopmental Disorders, National Center of Neurology and Psychiatry, Japan, will recent his recent work on “ADHD: Genes and risk for other conditions”. Attention deficit hyperactivity disorder (ADHD) is genetically correlated with physical conditions such as sleep disorders4, metabolic disorders5, and inflammatory disorders6. Using data from a longitudinal birth cohort study in Japan, we identified common pathways that contribute to these conditions. Targeting these pathways may help manage both ADHD and related physical problems.
Prof Katya Rubia, PhD., Deputy Head of Department, Department of Child & Adolescent Psychiatry, Section of Developmental Neuroimaging, Head, Institute of Psychiatry, Psychology & Neurosciences, King’s College London, UK. The title of her talk is “Neurotherapies for ADHD: do they work?”. ADHD medications are effective, but evidence for longer-term efficacy is limited and users prefer non-pharmacological treatments due to side effects. Neuromodulation has emerged as a potential novel neuroplastic non-drug treatment solution for ADHD. I will present and discuss our RCT findings on the efficacy of fMRI-Neurofeedback7 and of non-invasive brain stimulation including transcranial direct current stimulation (tDCS)8 and trigeminal nerve stimulation (TNS)9.
Together, these talks will provide a comprehensive overview of recent developments in neurocognitive pathways, genetic risk factors, neuromodulation treatments of ADHD. The symposium aims to bridge between mechanism discovery and treatment development in the big-data era of mental health research.
Prof Qiang Luo, PhD., Director, Centre for Computational Psychiatry, Institute of Brain Inspired Intelligence at Fudan University (P.R. China), will discuss his recent work on “ADHD: neurocognitive pathways”. ADHD is characterized by its clinical heterogeneity in symptoms and their trajectories1. However, both cognitive impairment and motivational dysfunction in the well-known ‘dual-pathway model for ADHD’ can be absent in about 30% of ADHD cases and cannot predict the persistence or remitting of the symptoms. He will present and discuss the emerging evidence that highlights the emotion dysregulation, proposing a new three-pathway model2, and the prediction of symptom course by longitudinal neuroimaging changes3.
Dr. Nagahide Takahashi, MD., PhD., Director, Department of Neurodevelopmental Disorders, National Center of Neurology and Psychiatry, Japan, will recent his recent work on “ADHD: Genes and risk for other conditions”. Attention deficit hyperactivity disorder (ADHD) is genetically correlated with physical conditions such as sleep disorders4, metabolic disorders5, and inflammatory disorders6. Using data from a longitudinal birth cohort study in Japan, we identified common pathways that contribute to these conditions. Targeting these pathways may help manage both ADHD and related physical problems.
Prof Katya Rubia, PhD., Deputy Head of Department, Department of Child & Adolescent Psychiatry, Section of Developmental Neuroimaging, Head, Institute of Psychiatry, Psychology & Neurosciences, King’s College London, UK. The title of her talk is “Neurotherapies for ADHD: do they work?”. ADHD medications are effective, but evidence for longer-term efficacy is limited and users prefer non-pharmacological treatments due to side effects. Neuromodulation has emerged as a potential novel neuroplastic non-drug treatment solution for ADHD. I will present and discuss our RCT findings on the efficacy of fMRI-Neurofeedback7 and of non-invasive brain stimulation including transcranial direct current stimulation (tDCS)8 and trigeminal nerve stimulation (TNS)9.
Together, these talks will provide a comprehensive overview of recent developments in neurocognitive pathways, genetic risk factors, neuromodulation treatments of ADHD. The symposium aims to bridge between mechanism discovery and treatment development in the big-data era of mental health research.
11:15 AM – 11:40 AM
25 min
25 min
11:40 AM – 12:05 PM
25 min
25 min